We have not seen the spectacular run that many of the biotechnology and genomics concerns have seen, but nor have we suffered the precipitous corrections experienced by a number of those stocks over the last ten days. Elan is one of the better-performing pharmaceutical stocks this year a year that isn't going to be stellar for the industry. Yes, that is one of our research activities. We have Antegren, a monoclonal antibody in development for MS, and a small molecule program in collaboration with Wyeth-Ayerst. MS is one of the targets of that joint effort.
Transdermal technology is one of the technologies offered by our drug delivery division.
For our own proprietary purposes, we have some things in development that also use the transdermal patch. For example, over the next several years we hope to develop Permax, which we currently market, in a transdermal formulation. That sounds like a very significant development. Permax is currently indicated as an adjunctive treatment of Parkinson's disease, and it's our hope that the transdermal version might be developed as monotherapy. All companies are vulnerable to pipeline disappointments, and we had our share of those in 1999.